TUCSON, Ariz., Jan. 9, 2025 /PRNewswire/ -- SynCardia Systems, LLC ("SynCardia" or the "Company"), a subsidiary of Picard Medical, Inc. and a frontrunner in total artificial heart innovations, is excited to share that the China National Intellectual Property Administration ("CNIPA") has officially informed the Company of its decision to award SynCardia its inaugural patent for the next-generation total artificial heart. This patent outlines groundbreaking technology designed to remove external drive mechanisms by completely embedding the pumping function within the implanted artificial heart ventricle.
This achievement marks a crucial advancement in SynCardia's goal of developing a completely implantable total artificial heart, known as the "Emperor." This device aims to offer a life-saving alternative for patients facing severe heart failure globally. The latest iteration of the Emperor artificial heart enhances SynCardia's established total artificial heart technology, incorporating new features designed to improve patient recovery and broaden access to essential cardiac support.
"We are excited to get this news from CNIPA, as it underscores the worldwide significance of our goal to enhance our artificial heart technology," stated Patrick NJ Schnegelsberg, CEO of SynCardia Systems. "This patent plays a vital role in our plan to deliver the SynCardia Total Artificial Heart and the upcoming Emperor artificial heart to patients in China."
SynCardia is dedicated to leading innovations in its artificial heart technology and broadening its market presence. The company actively collaborates with global regulatory authorities and partners to guarantee that both its existing and next-generation total artificial heart will be accessible to patients around the globe in the future.
Information on SynCardia Systems, LLC
SynCardia Systems, LLC stands at the forefront of total artificial heart innovation. The company offers the SynCardia Total Artificial Heart ("STAH"), which holds the distinction of being the sole artificial heart approved by both the U.S. Food and Drug Administration and Health Canada. To date, the STAH has been successfully implemented in more than 2,100 patients around the globe.
Statements Regarding Future Expectations
This press release contains statements that are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and can generally be identified by the use of future dates or words such as "aim," "vision," "strategy," "remain," "or "continue" or the negative of such terms and other comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, risks, and uncertainties that could cause actual results to differ materially from such estimates or forecasts. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information in this press release. Such forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release except as required by law. Forward-looking statements in this press release may include, for example, statements about: the patent's ability to eliminate external drive mechanisms by fully integrating the pumping mechanism within the implanted artificial heart ventricle, the vision of a fully implantable total artificial heart, improving patient outcomes and expanding accessibility to life-saving cardiac support, our strategy to bring the SynCardia Total Artificial Heart and the next generation Emperor artificial heart to patients in China and our continued work with international regulatory bodies and partners to ensure the future availability of its current and next-generation total artificial heart to patients worldwide.
For media inquiries or further information, please contact the SynCardia Promotional Team via email [email protected].
Press Inquiry:
Promotional Team
[email protected]
520-545-1234
- The SynCardia temporary Total Artificial Heart (the TAH-t) is indicated for use as a bridge to transplantation in cardiac transplant-eligible candidates at risk of imminent death from biventricular failure.
